Unfractionated Heparin Dosing Without IV Infusion
For therapeutic anticoagulation without IV infusion, administer subcutaneous unfractionated heparin with an initial dose of 333 U/kg followed by 250 U/kg every 12 hours, without routine aPTT monitoring. This fixed-dose, weight-based regimen is as effective and safe as low-molecular-weight heparin for treating venous thromboembolism and is suitable for outpatient management 1, 2.
Therapeutic Anticoagulation Regimens
Subcutaneous UFH for VTE Treatment
The evidence strongly supports fixed-dose subcutaneous heparin:
- Initial bolus: 333 U/kg subcutaneously
- Maintenance: 250 U/kg subcutaneously every 12 hours
- No aPTT monitoring required with this weight-based approach 1
The FIDO trial demonstrated this regimen achieved equivalent outcomes to LMWH, with recurrent VTE rates of 3.8% vs 3.4% and major bleeding of 1.1% vs 1.4% 1. Importantly, 72% of patients were treated entirely as outpatients 1.
Alternative FDA-Approved Regimen
The FDA label provides an alternative approach 3:
- Initial dose: 5,000 units IV bolus, followed by 10,000-20,000 units subcutaneously
- Maintenance options:
- 8,000-10,000 units every 12 hours, OR
- 15,000-20,000 units every 8 hours
This traditional regimen requires aPTT monitoring 4-6 hours after injection, targeting 1.5-2.0 times control (50-70 seconds) 4, 3.
VTE Prophylaxis Dosing
For hospitalized patients requiring prophylaxis:
- Standard dose: 5,000 units subcutaneously every 8-12 hours 5, 6
- Duration: Continue throughout hospitalization or until fully ambulatory 5
- No routine monitoring needed for prophylactic dosing 5
The every-8-hour regimen appears more effective than every-12-hour dosing, though both are used 7.
Special Populations
Renal Impairment (ESRD)
For patients with end-stage renal disease where LMWH is contraindicated:
- Use fixed-dose subcutaneous UFH: approximately 223-245 U/kg every 12 hours
- No monitoring required
- LMWH accumulates dangerously with CrCl <30 mL/min, making UFH the preferred option 8
Obesity
Critical caveat: Obese patients require lower weight-adjusted doses to achieve target anticoagulation. Body mass index was the only significant predictor of heparin response after weight-based dosing 9. Consider using actual body weight but anticipate achieving therapeutic levels with lower U/kg doses.
Pregnancy
For hospitalized antepartum patients receiving prophylaxis:
- First trimester: 5,000 units every 12 hours
- Second trimester: 7,500 units every 12 hours
- Third trimester: 10,000 units every 12 hours
Important warning: With 7,500-10,000 units every 12 hours, 15-19% of patients develop aPTT >40 seconds, which may impact neuraxial anesthesia timing 10.
Key Advantages of Subcutaneous UFH
- Suitable for outpatient treatment - no hospitalization required 1
- No routine monitoring needed with fixed weight-based dosing 1, 2
- Preferred in severe renal failure (CrCl <30 mL/min) over LMWH 6, 8
- Cost-effective alternative to LMWH 8
- Rapid reversibility with protamine if needed
Critical Monitoring Requirements
Even without aPTT monitoring for dose adjustment:
- Platelet counts: Every 2-3 days from day 4-14 to screen for heparin-induced thrombocytopenia (HIT risk up to 5%) 11
- Hemoglobin/hematocrit: Every 2-3 days up to day 14 6
- Occult blood in stool: Periodically throughout therapy 4
When to Avoid Subcutaneous UFH
Absolute contraindications 5:
- Active major bleeding (>2 units transfused in 24 hours)
- Recent CNS bleed or high-risk intracranial/spinal lesion
- Concurrent spinal anesthesia/lumbar puncture
Relative contraindications 5:
- Thrombocytopenia (platelets <50,000/mcL)
- Severe platelet dysfunction
- Recent major surgery at high bleeding risk
Practical Administration
- Use deep subcutaneous injection in the abdominal fat layer (above iliac crest) or upper thigh 4, 3
- Rotate injection sites to prevent hematoma formation 3
- Use fine needle (25-26 gauge) to minimize tissue trauma 3
- Never use intramuscular route - high risk of hematoma 4
Bridging to Warfarin
When transitioning to warfarin:
- Start warfarin concurrently with heparin
- Continue full-dose heparin for minimum 5 days AND until INR therapeutic (2-3) for 2 consecutive days 4
- No tapering required - discontinue abruptly once INR therapeutic 4, 3
Important: Warfarin directly increases aPTT by approximately 20 seconds for each 1.0 increase in INR, which can confuse monitoring if using aPTT-adjusted dosing 12.